Related references
Note: Only part of the references are listed.Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
Stephen J. Schuster et al.
LANCET ONCOLOGY (2021)
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
Yaqing Cao et al.
FRONTIERS IN ONCOLOGY (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report
Christopher Ronald Funk et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Elise A. Chong et al.
BLOOD (2017)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)